Government continues to support owners having engaged Will Power and Prestige
The Police and the Independent Commission Against Corruption stated earlier today (June 10) that they had laid charges against Will Power Architects Company Limited (Will Power) and Prestige Construction & Engineering Co., Limited (Prestige), as well as seven individuals who played different roles in the major maintenance project of Wang Fuk Court. The Government understands that some buildings and housing estates have hired these two companies as consultant or contractor for their building maintenance works. As the individuals and companies involved will no longer be able to perform their duties for the works, the Government is providing appropriate support to assist these owners in following up the relevant works having regard to their circumstances.
Wang Fuk Court, Photo by Bastille Post
For owners who have engaged Will Power as their consultant with the maintenance works commenced, the Urban Renewal Authority (URA) announced yesterday (June 9) that it would provide transitional arrangement free-of-charge for approximately 37 cases that have received URA's building rehabilitation subsidies or support services, so as to assist the owners in engaging an Independent Reviewer to promptly conduct third-party assessment, clarify the fees for the completed but not yet paid works so that the owners' corporations (OCs)/ owners can pay to the contractors, as well as prepare tender documents for the appointment of a new works consultant. As for a few cases that are not URA's original clients, the URA may also provide such transitional arrangement on a fee-paying basis. Please refer to the press release issued by the URA for details (www.ura.org.hk/en/news-centre/press-releases/20260609).
As for cases where Will Power has been engaged as consultant but yet to sign the works contract with the contractor, the owners should first terminate the contract with Will Power, and then consider engaging a new works consultant through the enhanced "Smart Tender" to be launched by the Government and the URA. In this connection, in order to facilitate owners' termination of the consultancy services of Will Power, the Development Bureau (DEVB) has, in consultation with the URA and the Hong Kong Institute of Surveyors (HKIS), compiled a set of reference materials to provide advice to the OCs on the termination of the consultancy services of Will Power and follow-up matters. The District Offices will contact the affected OCs and owners through their district networks to provide relevant reference materials and arrange briefings by the URA and the HKIS to these OCs and owners where necessary.
The Development Bureau, Photo source: reference image
In addition, regarding cases where Prestige has been engaged as the contractor while their consultant is not Will Power, since qualified consultants have been engaged for these maintenance works, the consultants have the responsibility to assist owners in supervising their contractors' work and addressing any issues that arise during the course of the works. Hence, the owners should discuss possible solutions with their consultants, including terminating the existing works contracts, and consider seeking legal advice where necessary. The District Offices will continue to contact the affected OCs and owners through their district networks to provide appropriate support.
If buildings have received Mandatory Building Inspection Scheme notices and the compliance period has expired or will expire shortly, the Buildings Department (BD) will exercise discretion on a case-by-case basis.
The Buildings Department, Photo source: reference image
Furthermore, a DEVB spokesman said that the BD had removed Prestige from the register of general building contractors in February this year. However, this will not exempt Prestige or the relevant individuals from criminal liabilities under the Buildings Ordinance. For contractors, registered inspectors and other involved persons who have violated the Ordinance, the BD will separately take prosecution actions and impose penalties having regard to the investigation results.
DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards
The Department of Health (DH) today (July 14) convened the 14th Meeting of the International Advisory Board (IAB) on Hong Kong Chinese Materia Medica Standards (HKCMMS) to review the reference standards for 16 types of Chinese Materia Medica (CMM) commonly used in Hong Kong, and to discuss the future development of the HKCMMS. Over 60 experts from the Chinese Mainland, overseas and Hong Kong attended the meeting.
Since 2002, the DH has been implementing the HKCMMS project in phases to develop standards for commonly used CMM in Hong Kong to ensure their safety and quality.
In his opening remarks, the Director of Health and the Chairperson of the IAB, Dr Ronald Lam, said, "One of the key initiatives of the Government Chinese Medicines Testing Institute (GCMTI) under the DH is the implementation of the HKCMMS. With the publication of the Volume 12 of the HKCMMS, standards for 357 types of CMM have been established so far. They have become widely recognised international reference standards for Chinese medicine testing and certification, thereby promoting the high-quality scientific development of Chinese medicine. In addition, the work of GCMTI is closely aligned with national priorities. The National 15th Five-Year Plan made it clear that we need to 'advance the inheritance and innovation of Chinese medicine' and 'promote the integration of Chinese and Western medicine'. It also calls for us to 'strengthen the conservation and utilisation of Chinese medicine resources', 'improve the quality of Chinese medicine, and build up and strengthen the Chinese medicine industry'. These are exactly the goals that the HKCMMS Project is helping to achieve - by setting rigorous quality standards for CMM and conducting applied research and development on testing methods that underpin the entire industry, establishing the Hong Kong Special Administrative Region as a bridgehead for the global expansion of Chinese Medicine."
Dr Lam emphasised that the success of the HKCMMS project depends on the active collaboration of stakeholders across different sectors. He expressed his sincere appreciation to the four research partners attending the meeting, commending their dedicated contributions to advancing the project's research efforts. They were the National Institutes for Food and Drug Control, the Chinese University of Hong Kong, the Hong Kong Polytechnic University and the China Medical University. He also thanked the Government Laboratory for conducting inter-laboratory verification studies. Dr Lam emphasised that these collaborations are crucial for establishing a rigorous and solid scientific foundation for the HKCMMS and gaining international credibility. The DH is also deeply grateful to the National Medical Products Administration, the National Administration of Traditional Chinese Medicine and the Chinese Pharmacopoeia Commission for their continuous valuable advice and support in developing the HKCMMS. To align with the National 15th Five-Year Plan to advance the inheritance, innovation and high-quality development of Chinese medicine, expand and promote Chinese medicine culture, the DH will continue to steadfastly promote the development of Chinese medicine and better integrate into and serve the overall national development.
The two-day meeting brought together experts from the Chinese Mainland, Australia, Austria, Canada, Germany, Japan, Thailand, the United Kingdom and the United States, as well as representatives from research institutions, the DH and the Government Laboratory of the Hong Kong Special Administrative Region. The 16 types of CMM commonly used in Hong Kong that were discussed at the meeting included Bambusae Caulis in Taenias, Pyrolae Herba, Natrii Sulfas, Dichroae Radix, Dioscoreae Hypoglaucae Rhizoma, Cynanchi Atrati Radix et Rhizoma, Jasmini Flos, Tinosporae Caulis, Inulae Flos, Haematitum, Lasiosphaera seu Calvatia, Vespae Nidus, Dioscoreae Rhizoma, Aconiti Kusnezoffii Folium, Meliae Cortex and Tripterygii Wilfordii Radix.
Previous editions of the HKCMMS can be accessed at the website of the Chinese Medicine Regulatory Office of the DH.
DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards Source: HKSAR Government Press Releases
DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards Source: HKSAR Government Press Releases
DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards Source: HKSAR Government Press Releases
